Data from the UK Drug Administration Authority revealed that the famous weight loss drugs, which include Monjoiro, Wigofi, and Ozmbeek, are linked to a possible serious side effect, may lead to death, which is pancreatitis.
According to the Medicines Regulatory Authority, 181 cases of acute or chronic pancreatitis linked to Monjoo, with five deaths, were recorded compared to 113 cases and one death that was linked to Wigofi and Ozmbeek, according to the British Sky News network.
Professor Matt Brown, chief scientific official at the Genomex Ingand, affiliated to the Ministry of Health and Social Welfare, said: “Weight loss drugs such as Wigofi and Ozmbeck are the headlines, but as is the case with all medications, their use may cause serious side effects,” said Professor Matt Brown, the chief scientific official at the Genomex Ingand, affiliated to the Ministry of Health and Social Welfare.
He added, “We believe that there is a real possibility to reduce these side effects, as many of them are due to genetic reasons. This is what we study at the present time. ”
The main symptoms of pancreatitis are severe pain in the middle of the abdomen, fever, and nausea. Hospital acute cases are treated with fluids and oxygen, and they usually recover within a few days.
But complications may occur, and about 5 percent of severe cases lead to death.
Commenting on the new data, some health experts said that there is no evidence that the drugs have caused the deaths directly. Also, the evidence is not strong enough to restrict the drug regulations to access these drugs.
For people with type 2 diabetes or obesity, there are clear benefits for using these medications. It reduces blood sugar levels, leads to rapid weight loss, and reduces deaths from cardiovascular disease by five.
But for people with a slight increase in weight, the health benefits of these drugs are much less clear.
Lily, the manufacturer of the Monjao drug in the United Kingdom, stated that patient safety is its “maximum priority.”
She added in a statement that the patient’s information bulletin, “warns that pancreatitis is one of the uncommon side effects (which may affect up to one person in every 100 people).”
Lily also advises patients to consult their doctor or any other health care specialist before using Monjoo if they had previously had pancreatitis.
Likewise, the company “Novo Nordisk”, which manufactured for both Wigofi and Ozmebek, said in a statement that “the safety of patients is of the utmost importance to us.” As with all medications, side effects may occur and vary from patient to patient. The known risks and benefits of our addiction have been described in the summary of the product properties.
The company recommended the patients to take these medications only under the careful supervision of a health care specialist.
